prurigo nodularis Phase 2 trial
Tempus AI’s $1.5 Billion Personalis Deal and Celldex’s Phase 2 Miss This Week
BridgeBio’s rare disease drug cleared its first FDA hurdle on July 22. Celldex’s itch drug cleared every hurdle except the one that mattered, on July 21, one day earlier. One is a step closer to patients. The other proved its mechanism worked in a lab sense and got shelved anyway. In between, Tempus AI put…
